ClinicalTrials.gg

Program

AMG 732

A development code.

Its studies are mostly in Graves Ophthalmopathy, led by Amgen.

Furthest: phase 2, since May 2, 20242 company-led studies, 2 open or runningNext primary completion: Jan 6, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen22 open or runningphase 2since May 2, 2024May 2, 2024Jan 6, 2027phase 2 · NCT06401044

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2024First study: phase 2 study in Graves OphthalmopathyFirst studyNCT06401044 · 94 enrolled · United States, Australia, Canada and more
  2. Feb 23, 2026Phase 2 study in Graves OphthalmopathyNCT07438405 · 30 planned · United States, Poland, Spain and more

Ahead

  1. Jan 6, 2027Primary completion: phase 2 study in Graves OphthalmopathyNCT06401044
  2. Jan 29, 2028Primary completion: phase 2 study in Graves OphthalmopathyNCT07438405

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07438405Graves Ophthalmopathy · United States, Poland, Spain and more2RecruitingJan 29, 202830
NCT06401044Graves Ophthalmopathy · United States, Australia, Canada and more2Active, not recruitingJan 6, 202794

How it is read

Names in the registry

  • “AMG 732”, 2 entries

Codes read as this program: AMG732.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.